Trump Obesity Drug Deal Boosts Pharma Stocks
Major pharmaceutical giants Novo Nordisk and Eli Lilly experience significant stock surges as former President Donald Trump considers a groundbreaking obesity drug partnership, potentially revolutionizing weight loss treatment accessibility.